

March 2026 Pharmacy & Therapeutics Committee Decisions

Aspirus' Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to review and make changes to the Aspirus Medicare Formulary (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for Medicare formularies are tentative until Aspirus receives final CMS approval.

Key

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

NEW DRUG REVIEW			
DRUG	INDICATION	FORMULARY COVERAGE	EFFECTIVE DATE
Andembry (garadacimab-gxii)	Prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older	Non-Formulary	NA
Dawnzera (donidalorsen)	Prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older	Non-Formulary	NA
Anzupgo (delgocitinib)	Moderate to severe chronic hand eczema (CHE) in adults who have an inadequate response to, or for whom topical corticosteroids are not advisable	Non-Formulary	NA
Brinsupri (brensocatib)	Non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients ≥12 years	Non-Formulary	NA

March 2026 Pharmacy & Therapeutics Committee Decisions

Leqselvi (deuruxolitinib)	Treatment of adult patients with severe alopecia areata (AA)	Non-Formulary	NA
Modeyso (dordaviprone) Protected Class	Adult and pediatric patients ≥ 1 year of age with diffuse midline glioma (DMG) harboring an H3 K27M mutation with progressive disease following prior therapy	Formulary w/PA	NA
Sephience (sepiapterin)	Treatment of hyperphenylalaninemia (HPA) in patients aged 1 month and older with sepiapterin-responsive phenylketonuria (PKU). To be used in conjunction with a phenylalanine (PHE)-restricted diet.	Non-Formulary	NA
Ekterly (sebetralstat)	Treatment of acute attacks of hereditary angioedema (HAE) in patients aged 12 years and older.	Non-Formulary	NA
Hernexeos (zongertinib)	Treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have human epidermal growth factor receptor 2 (HER2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.	Formulary w/PA	NA
Ensacove (ensartinib)	Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive (ALK+) locally advanced or metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have not previously received an ALK-inhibitor.	Formulary w/PA	NA

March 2026 Pharmacy & Therapeutics Committee Decisions

Formulary changes for New Generics, New Indications and Miscellaneous Previously Reviewed drugs are effective 04/1/2026.

NEW INDICATIONS REVIEW		
DRUG	CURRENT FORMULARY STATUS	RECOMMENDATION
Caplyta (lumateperone) 10.5, 21, & 42 mg capsules for major depressive disorder	Formulary	No change
Rinvoq (upadacitinib) 15, 30, & 45 mg extended-release tablets & 1 mg/mL oral solution updated indications for ulcerative colitis and Crohn disease	Formulary	No change
Koselugo (selumetinib) 10 & 25 mg capsules and 5 & 7.5 mg sprinkle capsules for adults with neurofibromatosis type 1	Formulary	No change
Tezspire (tezepelumab) 210 mg injection for add-on maintenance treatment of adult and pediatric patients = 12 years of age with chronic rhinosinusitis with nasal polyps (CRSwNP)	Non-Formulary	No change
Darzalex Faspro (daratumumab-hyaluronidase) 1,800 mg-30,000 units/15 mL SQ vial for high-risk smoldering multiple myeloma	Non-Formulary	No change
Eylea HD (aflibercept) 8 mg intravitreal vial for macular edema	Non-Formulary	No change

March 2026 Pharmacy & Therapeutics Committee Decisions

following retinal vein occlusion		
<p>Keytruda [Qlex] (pembrolizumab [+berahyaluronidase alfa]) + Padcev (enfortumab vedotin) as neoadjuvant tx & continued after cystectomy as adjuvant tx in adults with muscle invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy</p>	Non-Formulary	No change
<p>Imfinzi (durvalumab) 50 mg/mL IV vials in combination with fluorouracil, leucovorin, oxaliplatin, & docetaxel as neoadjuvant and adjuvant treatment followed by single-agent durvalumab for adults with resectable gastric or gastroesophageal junction adenocarcinoma</p>	Non- Formulary	No change
<p>Epkinly (epcoritamab) 4 mg/0.8 mL & 48 mg/0.8 mL SQ vials (1) in combination with lenalidomide and rituximab for adults with relapsed or refractory (R/R) follicular lymphoma (FL) (2) traditional approval for R/R FL after = 2 lines of systemic therapy</p>	Non-Formulary	No change
<p>Linzess (linaclotide) 145 mcg capsules for irritable bowel syndrome with constipation (IBS-C) in pediatrics ≥ 7 years (age expansion)</p>	Formulary	No change

March 2026 Pharmacy & Therapeutics Committee Decisions

<p>Akeega (niraparib-abiraterone) 50-500 & 100-500 mg tablets for BRCA2-mutated metastatic castration-sensitive prostate cancer</p>	<p>Formulary</p>	<p>No change</p>
<p>Rubraca (rucaparib) 200, 250, & 300 mg tablets for deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer for patients previously treated with androgen receptor-directed therapyrefractory follicular lymphoma</p>	<p>Formulary</p>	<p>No change</p>
<p>Jaypirca (pirtobrutinib) 50 & 100 mg tablets for R/R chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor</p>	<p>Formulary</p>	<p>No change</p>
<p>Cablivi (caplacizumab) 11 mg IV vials for patients \geq 12 years of age with acquired thrombotic thrombocytopenic purpura</p>	<p>Formulary</p>	<p>No change</p>
<p>Furoscix (furosemide) 80 mg/10 mL SQ cartridge kit for pediatric patients weighing \geq 43 kg for treatment of edema associated with chronic heart failure or chronic kidney disease</p>	<p>Non-Formulary</p>	<p>No change</p>
<p>Accrufer (ferric maltol) 30 mg capsules for iron deficiency in patients \geq 10 years of age</p>	<p>Non-Formulary</p>	<p>No change</p>

March 2026 Pharmacy & Therapeutics Committee Decisions

<p>Mounjaro (tirzepatide) pens & vials for type 2 diabetes mellitus in patients \geq 10 years of age</p>	<p>Formulary</p>	<p>No change</p>
<p>Uplizna (inebilizumab) 10 mg/mL IV vials for generalized myasthenia gravis</p>	<p>Non-Formulary</p>	<p>No change</p>
<p>Enhertu (fam-trastuzumab) in combination with Perjeta (pertuzumab) as first-line treatment for unresectable or metastatic HER2-positive breast cancer</p>	<p>Non-Formulary</p>	<p>No change</p>
<p>Nexplanon (etonogestrel) 68 mg implant for prevention of pregnancy for up to 5 years</p>	<p>Formulary</p>	<p>No change</p>
<p>Noxafil (posaconazole) 100 mg delayed-release tablets, 40 mg/mL oral suspension, & 300 mg powder for oral suspension for invasive aspergillosis in patients \geq 2 years of age</p>	<p>Formulary</p>	<p>No change</p>
<p>Opdivo Qvantig (nivolumab-hyaluronidase) 120 mg-2,000 units/mL SQ vials new indications & age expansion: monotherapy for CRC and HCC following nivolumab and ipilimumab AND approved in patients aged \geq 12 years for CRC indications</p>	<p>Non-Formulary</p>	<p>No change</p>

March 2026 Pharmacy & Therapeutics Committee Decisions

<p>Cerezyme (imiglucerase) 400 unit IV vial for non-CNS manifestations of type 1 or type 3 Gaucher disease</p>	<p>Non-Formulary</p>	<p>No change</p>
---	----------------------	------------------

NEW GENERICS REVIEW		
DRUG	RATIONALE/ALTERNATIVE	RECOMMENDATION
<p>Starjemza (ustekinumab) 45 mg/0.5 mL SQ vial & PFS and 90 mg/mL PFS</p>	<p>New biosimilar for Stelara has launched</p>	<p>Formulary</p>
<p>Hallog (halcinonide) 0.1% topical solution for dermatoses</p>	<p>A generic halcinonide solution has launched with no difference in list prices to the branded agent, Halog. As this branded product was already not covered, both brand and generic will remain not covered.</p>	<p>Non-Formulary</p>
<p>Gleostine (lomustine) 10, 40, & 100 mg capsules for brain tumors & Hodgkin lymphoma</p>	<p>A generic lomustine capsule has launched for all strengths currently on the market for branded Gleostine. The new generic product is approximately a 14% discount from the branded list prices.</p>	<p>Formulary</p>
<p>Premarin (conjugated estrogens) 0.3, 0.45, 0.625, 0.9, & 1.25 mg tablets for menopausal symptoms, hypoestrogenism, and palliation for breast & prostate cancer</p>	<p>A generic for Premarin tablets has launched. The brand name was not covered and the generic will remain not covered.</p>	<p>Non-Formulary</p>

March 2026 Pharmacy & Therapeutics Committee Decisions

Mavenclad (cladribine) 10 mg tablets for multiple sclerosis	Generic cladribine recently launched at approximately a 20% discount to the brand.	Non-Formulary
Fycompa (perampanel) 0.5 mg/mL oral suspension for epilepsy	Perampanel (Fycompa equiv) oral suspension has launched at a limited price reduction vs brand.	Formulary
Zylet (loteprednol-tobramycin) 0.5-0.3% ophthalmic suspension antibiotic & corticosteroid combo for ocular conditions	Loteprednol/tobramycin recently had a generic launch.	Non-Formulary
Besivance (besifloxacin) 0.6% ophthalmic suspension for bacterial conjunctivitis	Besifloxacin had a recent AG launch which was accompanied by a limited price decrease.	Non-Formulary

New or Expanded Formulations		
DRUG	RATIONALE/ALTERNATIVE	RECOMMENDATION
Leqembi Iqlik (lecanemab) 360 mg/1.8 mL autoinjector for Alzheimer disease	Lecanemab is now available as a SQ autoinjector approved for weekly maintenance treatment of Alzheimer disease following the completion of at least 18 months of IV treatment. SQ lecanemab can be administered by the patient or caregiver, allowing for at-home administration.	Non-Formulary
Pazopanib 400 mg tablets for renal cell carcinoma & soft tissue sarcoma	A 400 mg strength of pazopanib recently launched in Medispan. Pazopanib (Votrient equiv) is generically available as 200 mg tablets which are covered on	Non-Formulary

March 2026 Pharmacy & Therapeutics Committee Decisions

	formulary and have MAC pricing.	
Subvenite (lamotrigine) 10 mg/mL oral suspension for epilepsy & bipolar disorder	Subvenite suspension is the first liquid formulation of lamotrigine to market, though generic ODT and chewable/dispersible tablets exist. A 1 mg/mL solution was previously commonly compounded with the IR tablets which are very low cost. Subvenite is \$3/mL or \$0.30 per mg.	Formulary
Tyvaso DPI (treprostinil) 80 mcg, 32/64 mcg, & 48/64 mcg powder cartridge maintenance kits for pulmonary arterial hypertension	A new higher strength of Tyvaso DPI has launched, adding an 80 mcg strength to the existing 16, 32, 48, and 64 mcg doses. Though the cost is notably higher (\$396 vs \$218) than existing strengths	Non-Formulary
Javadin (clonidine) 0.02 mg/mL oral solution for hypertension	Clonidine oral solution is now available for the treatment of hypertension in adults. With dosing normalized to an equivalent 0.1 mg tablet, the new dosage form is approximately 50x the cost.	Non- Formulary
Desloratadine 0.5 mg/mL oral solution for allergic rhinitis & urticaria	A very highly priced desloratadine solution has launched to the market. \$2,950 per bottle	Non- Formulary
Midazolam 10 mg/0.7 mL autoinjector for status epilepticus	This is an autoinjector form of midazolam that delivers 10 mg per injection for the disruption of status epilepticus.	Non-Formulary

March 2026 Pharmacy & Therapeutics Committee Decisions

<p>Vraylar (cariprazine) 0.5 mg & 0.75 mg capsules for schizophrenia in patients \geq 13 years of age & manic or mixed episodes associated with bipolar I disorder in patients \geq 10 years of age [new formulations & age expansions]</p>	<p>New lower strength 0.5 and 0.75 mg capsules of cariprazine are now available to accommodate an indication expansion into adolescents.</p>	<p>Formulary</p>
<p>Ranitidine 150 mg & 300 mg tablets for reducing gastric acid</p>	<p>Ranitidine tablets have relaunched but only as prescription, in 2 different strengths from the same manufacturer. The 150 mg tablet has a unit WAC price of \$6.63 and the 300 mg tablet has a unit WAC of \$12.04.</p>	<p>Non-Formulary</p>
<p>Pokonza (potassium chloride) 15 mEq powder packets for hypokalemia</p>	<p>A new strength of potassium chloride packets launched, available as 15 mEq packets under the brand name Pokonza. The new 15 mEq packets have a unit WAC of \$43.04. The 20 mEq packets are available generically and have a MAC of ~ \$1.25.</p>	<p>Non- Formulary</p>
<p>Potassium chloride 40 mEq powder packet for hypokalemia</p>	<p>Another new strength of potassium chloride packets also launched, available as 40 mEq packets. The 40 mEq packets have a WAC of \$86.07 per packet</p>	<p>Non-Formulary</p>
<p>Xpovio (selinexor) 80 mg tablets for multiple myeloma & diffuse large B-cell</p>	<p>A new Xpovio pack has launched for the 80 mg once weekly dose. Previously available as 2 x 40 mg</p>	<p>Formulary</p>

March 2026 Pharmacy & Therapeutics Committee Decisions

lymphoma	tablets per week, the new pack has a single 80 mg tablet. There is no change to price per week.	
Cefixime 400 mg tablets for various susceptible infections	The tablet formulation of cefixime 400 mg recently re-launched following a long-term discontinuation. The capsule formulation has otherwise been available throughout this timeframe and is approximately half the cost.	Non-Formulary
Wegovy (semaglutide) 1.5, 4, 9, & 25 mg tablets for chronic weight management & MACE reduction	Semaglutide for weight management is now available in an oral tablet dosage form. The product carries the same indications for chronic weight management and reduction of cardiovascular risk but does not have an indication for the treatment of metabolic dysfunction-associated steatohepatitis.	Non-Formulary
Rybrevent Faspro (amivantamab-hyaluronidase) 1,600-20,000 mg-unit/10 mL & 2,240-28,000 mg-unit/14 mL SQ vials for EGFR-mutated NSCLC	This is a new formulation of amivantamab that allows for subcutaneous administration via addition of hyaluronidase. As with other subcutaneous hyaluronidase-based oncology formulations, this is still administered by a healthcare provider.	Non-Formulary
Aqvesme (mitapivat) 100 mg tablets for anemia in adults	A new 100 mg strength of mitapivat recently launched, as	Non-Formulary

March 2026 Pharmacy & Therapeutics Committee Decisions

with alpha- or beta-thalassemia	branded Aqvesme.	
Metoprolol tartrate 12.5 mg tablets for hypertension	A brand version of metoprolol tartrate launched as 12.5 mg tablets. Due to availability of several other generic strengths of metoprolol tartrate, including MAC-protected 25 mg tablets which can be cut in half	Non-Formulary
Daybue (trofinetide) 5,000, 6,000 & 8,000 mg powder packets for Rett syndrome	A new formulation of trofinetide has launched providing increased flexibility in storage and administration.	Non-Formulary
Orudis (ketoprofen) 75 mg capsules for pain & inflammation	Ketoprofen capsules had previously been discontinued from the market for several years. A new manufacturer has re-launched product under the brand name Orudis. This product is 40X higher cost than when previously available.	Non-Formulary
Sdamlo (amlodipine) 2.5, 5, & 10 mg single-dose bottles for oral solution for hypertension and coronary artery disease	Sdamlo is a new amlodipine powder for oral suspension product, which is unique in that it is available in single-dose cups that can be mixed at home.	Non-Formulary
Lunsumio Velo (mosunetuzumab) 5 mg/0.5 mL & 45 mg/mL SQ vials for follicular lymphoma	A subcutaneously administered version of Lunsumio (mosunetuzumab) recently launched, under the name Lunsumio Velo. Both mosunetuzumab products must be	Non-Formulary

March 2026 Pharmacy & Therapeutics Committee Decisions

	administered by a healthcare professional	
--	---	--

ADDITIONAL ITEMS REVIEWED	
ITEM	DRUGS WITH NEW POLICIES
New Medical Drug Policies (effective 05/15/2026)	<ul style="list-style-type: none"> Exdensur Itvisma Lunsumio Velo Rybrevant Faspro Yartemlea